西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察

Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer

目的研究西妥昔单抗联合化疗一线治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效。方法回顾性分析北京协和医院呼吸内科2008年11月至2012年4月使用西妥昔单抗联合化疗的20例非小细胞肺癌患者的临床资料,进行疗效和安全性评估。所有患者签署了知情同意书,并同意提供临床资料。结果截至分析之日尚有8例患者仍存活,最长1例用药后存活了39.8个月。客观反应率(ORR)、疾病控制率(DCR)、无进展生存(PFS)和总生存(OS)时间分别为50.0%、70.0%、8.6个月和10.9个月。常见的毒副反应包括皮肤毒性(15例,75.0%)、谷丙转氨酶升高(3例,15.0%)、血液系统毒性(2例,10.0%)、过敏(1例,5.0%)和发热(1例,5.0%)。结论 NSCLC患者使用西妥昔单抗联合化疗作为一线治疗疗效好,严重的毒副反应发生率低且可以控制,但尚需要寻找合适的预测性标记物来筛选治疗的受益人群。

Objective To evaluate the safety and efficacy of cetuximab combined with chemotherapy as first line therapy in patients with non-small cell lung cancer（NSCLC）.Methods A retrospective analysis of clinical data was conducted in 20 patients who were given cetuximab combined with chemotherapy as first line therapy in our department between November 2008 and April 2012.All patients signed the informed consent,and consented to offer clinical information.Results Eight patients were alive up to the time of our analysis,and the longest survival was 39.8 months.The objective response rate（ORR）,disease control rate（DCR）,median progression free survival（PFS）,and estimated least median overall survival（OS） were 50.0%,70.0%,8.6 months and 10.9 months,respectively.The common adverse events included skin toxicity（15,75.0%）,alanine aminotransferase elevation（3,15.0%）,hematological toxicity（2,10.0%）,allergy（1,5.0%） and fever（1,5.0%）.Conclusion Cetuximab combined with chemotherapy as first line therapy for patients with NSCLC has promising ORR,DCR,and PFS.Serious adverse events are of low incidence and quite controllable.We should search predictive factors for selecting appropriate patients.